OTC Markets OTCPK - Delayed Quote USD

Laboratorios Farmaceuticos Rovi, S.A. (LABFF)

65.86
-20.19
(-23.46%)
At close: July 1 at 3:24:24 PM EDT
Loading Chart for LABFF
  • Previous Close 86.05
  • Open 90.61
  • Bid --
  • Ask --
  • Day's Range 65.86 - 65.86
  • 52 Week Range 65.86 - 90.61
  • Volume 207
  • Avg. Volume 0
  • Market Cap (intraday) 3.369B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 21.04
  • EPS (TTM) 3.13
  • Earnings Date Jul 29, 2025 - Aug 4, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 14, 2025
  • 1y Target Est --

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

www.rovi.es

2,197

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LABFF

Ver más

Performance Overview: LABFF

Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .

YTD Return

LABFF
27.31%
IBEX 35... (^IBEX)
23.50%

1-Year Return

LABFF
22.52%
IBEX 35... (^IBEX)
24.50%

3-Year Return

LABFF
7,490.64%
IBEX 35... (^IBEX)
61.24%

5-Year Return

LABFF
20.74%
IBEX 35... (^IBEX)
80.98%

Comparar con: LABFF

Selecciona hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.

Statistics: LABFF

Ver más

Valuation Measures

Annual
As of 6/5/2025
  • Market Cap

    3.22B

  • Enterprise Value

    3.31B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.25%

  • Return on Assets (ttm)

    14.32%

  • Return on Equity (ttm)

    24.93%

  • Revenue (ttm)

    767.47M

  • Net Income Avi to Common (ttm)

    140.02M

  • Diluted EPS (ttm)

    3.13

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.31M

  • Total Debt/Equity (mrq)

    18.08%

  • Levered Free Cash Flow (ttm)

    47.38M

Research Analysis: LABFF

Ver más

Company Insights: LABFF

Informes de investigación: LABFF

Ver más

People Also Watch